Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Resmetirom, is a liver-directed, -selective THR agonist, developed by Madrigal, administered orally once daily, that is being tested in the phase 3 trial
Includes 4 weeks of medication, sterile syringes, alcohol wipes, and a sharps disposal container
/assets/images/provider/photos/2701194.jpg)
They also saw a smaller but meaningful increase in PYY (about 70% over control)
One-Year Treatment With Exenatide Improves _-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
This drug is part of the glucagon-like peptide-1 (GLP-1) receptor agonists class of medications
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
